ADCT vs TECH · rev $70.8M vs P/E 65, rev $1.22B
ADC Therapeutics SA (ADCT) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported ADCT revenue for 2024-12-31 was $70.8M. Net income was -$157.8M. Revenue was up 1.8% from 2023-12-31 to 2024-12-31. ADCT currently screens at market cap $141.2M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
ADCT currently screens at market cap $141.2M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the ADCT and TECH stock pages for the full models.
Not investment advice.